Baricitinibis approved for use in the treatment of adults with moderately to severely active rheumatoid arthritis. Credit: Photo by Thought Catalog on Unsplash.

Eli Lilly and Company and its study partner Incyte has reported positive top-line results from the Phase III BREEZE-AD1 and BREEZE-AD2 trials after the studies met their primary endpoints.

Both trials are investigating the efficacy and safety of baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

AD is a chronic, relapsing skin disease that causes intense itching, dry skin, and inflammation on any part of the body.

The latest data shows that a statistically important proportion of patients receiving baricitinib achieved the primary endpoint at week 16 as assessed by the Global Assessment for AD (IGA) score of clear or almost clear as against the patients treated with placebo.

“We are encouraged that baricitinib met the primary endpoints in these two studies, and look forward to seeing the collective results of all five studies.”

Incidence of treatment-related adverse events and serious adverse events with baricitinib was similar to that of placebo.

Nasopharyngitis and headache were the most common treatment-related adverse events observed during the trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trials did not report any venous thromboembolic events (VTEs), major adverse cardiovascular events (MACE), or deaths.

Eli Lilly and Company immunology development vice-president Lotus Mallbris said: “Atopic dermatitis is a chronic inflammatory skin disease that can negatively impact the quality of life for patients, and unfortunately there are limited treatment options, particularly oral medications.

“We are encouraged that baricitinib met the primary endpoints in these two studies, and look forward to seeing the collective results of all five studies.”

Baricitinib previously received approval for use in over 50 countries for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).